HMG-CoA redutase (Galician Wikipedia)

Analysis of information sources in references of the Wikipedia article "HMG-CoA redutase" in Galician language version.

refsWebsite

Global rank Galician rank

19nih.gov

4^th place

6^th place

15doi.org

2^nd place

7^th place

1springer.com

274^th place

251^st place

1web.archive.org

1^st place

1jbc.org

4,455^th place

611^th place

1archive.org

6^th place

8^th place

archive.org

Witters LA, Kemp BE, Means AR (Jan 2006). "Chutes and Ladders: the search for protein kinases that act on AMPK". Trends in Biochemical Sciences 31 (1): 13–6. PMID 16356723. doi:10.1016/j.tibs.2005.11.009.

doi.org

dx.doi.org

Roitelman J, Olender EH, Bar-Nun S, Dunn WA, Simoni RD (Jun 1992). "Immunological evidence for eight spans in the membrane domain of 3-hydroxy-3-methylglutaryl coenzyme A reductase: implications for enzyme degradation in the endoplasmic reticulum". The Journal of Cell Biology 117 (5): 959–73. PMC 2289486. PMID 1374417. doi:10.1083/jcb.117.5.959.
Lindgren V, Luskey KL, Russell DW, Francke U (Dec 1985). "Human genes involved in cholesterol metabolism: chromosomal mapping of the loci for the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl-coenzyme A reductase with cDNA probes". Proceedings of the National Academy of Sciences of the United States of America 82 (24): 8567–71. PMC 390958. PMID 3866240. doi:10.1073/pnas.82.24.8567.
Farmer JA (1998). "Aggressive lipid therapy in the statin era". Progress in Cardiovascular Diseases 41 (2): 71–94. PMID 9790411. doi:10.1016/S0033-0620(98)80006-6.
Lin YL, Wang TH, Lee MH, Su NW (Jan 2008). "Biologically active components and nutraceuticals in the Monascus-fermented rice: a review". Applied Microbiology and Biotechnology 77 (5): 965–73. PMID 18038131. doi:10.1007/s00253-007-1256-6.
Arnaud C, Veillard NR, Mach F (Apr 2005). "Cholesterol-independent effects of statins in inflammation, immunomodulation and atherosclerosis". Current Drug Targets. Cardiovascular & Haematological Disorders 5 (2): 127–34. PMID 15853754. doi:10.2174/1568006043586198.
Sorrentino S, Landmesser U (Dec 2005). "Nonlipid-lowering effects of statins". Current Treatment Options in Cardiovascular Medicine 7 (6): 459–466. PMID 16283973. doi:10.1007/s11936-005-0031-1.
Thorpe JL, Doitsidou M, Ho SY, Raz E, Farber SA (Feb 2004). "Germ cell migration in zebrafish is dependent on HMGCoA reductase activity and prenylation". Developmental Cell 6 (2): 295–302. PMID 14960282. doi:10.1016/S1534-5807(04)00032-2.
Eisa-Beygi S, Hatch G, Noble S, Ekker M, Moon TW (Jan 2013). "The 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) pathway regulates developmental cerebral-vascular stability via prenylation-dependent signalling pathway". Developmental Biology 373 (2): 258–266. PMID 23206891. doi:10.1016/j.ydbio.2012.11.024.
Meigs TE, Roseman DS, Simoni RD (Apr 1996). "Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo". The Journal of Biological Chemistry 271 (14): 7916–22. PMID 8626470. doi:10.1074/jbc.271.14.7916. Arquivado dende o orixinal o 13 de outubro de 2008. Consultado o 22 de xaneiro de 2016.
Meigs TE, Simoni RD (Sep 1997). "Farnesol as a regulator of HMG-CoA reductase degradation: characterization and role of farnesyl pyrophosphatase". Archives of Biochemistry and Biophysics 345 (1): 1–9. PMID 9281305. doi:10.1006/abbi.1997.0200.
Keller RK, Zhao Z, Chambers C, Ness GC (Apr 1996). "Farnesol is not the nonsterol regulator mediating degradation of HMG-CoA reductase in rat liver". Archives of Biochemistry and Biophysics 328 (2): 324–30. PMID 8645011. doi:10.1006/abbi.1996.0180.
Istvan ES, Palnitkar M, Buchanan SK, Deisenhofer J (Mar 2000). "Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis". The EMBO Journal 19 (5): 819–30. PMC 305622. PMID 10698924. doi:10.1093/emboj/19.5.819.
Goldstein JL, Brown MS (Feb 1990). "Regulation of the mevalonate pathway". Nature 343 (6257): 425–30. PMID 1967820. doi:10.1038/343425a0.
Hardie DG, Scott JW, Pan DA, Hudson ER (Jul 2003). "Management of cellular energy by the AMP-activated protein kinase system". FEBS Letters 546 (1): 113–20. PMID 12829246. doi:10.1016/S0014-5793(03)00560-X.
Witters LA, Kemp BE, Means AR (Jan 2006). "Chutes and Ladders: the search for protein kinases that act on AMPK". Trends in Biochemical Sciences 31 (1): 13–6. PMID 16356723. doi:10.1016/j.tibs.2005.11.009.

jbc.org

Meigs TE, Roseman DS, Simoni RD (Apr 1996). "Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo". The Journal of Biological Chemistry 271 (14): 7916–22. PMID 8626470. doi:10.1074/jbc.271.14.7916. Arquivado dende o orixinal o 13 de outubro de 2008. Consultado o 22 de xaneiro de 2016.

nih.gov

ncbi.nlm.nih.gov

"Entrez Gene: HMGCR 3-hydroxy-3-methylglutaryl-Coenzyme A reductase".
Roitelman J, Olender EH, Bar-Nun S, Dunn WA, Simoni RD (Jun 1992). "Immunological evidence for eight spans in the membrane domain of 3-hydroxy-3-methylglutaryl coenzyme A reductase: implications for enzyme degradation in the endoplasmic reticulum". The Journal of Cell Biology 117 (5): 959–73. PMC 2289486. PMID 1374417. doi:10.1083/jcb.117.5.959.
Lindgren V, Luskey KL, Russell DW, Francke U (Dec 1985). "Human genes involved in cholesterol metabolism: chromosomal mapping of the loci for the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl-coenzyme A reductase with cDNA probes". Proceedings of the National Academy of Sciences of the United States of America 82 (24): 8567–71. PMC 390958. PMID 3866240. doi:10.1073/pnas.82.24.8567.
Farmer JA (1998). "Aggressive lipid therapy in the statin era". Progress in Cardiovascular Diseases 41 (2): 71–94. PMID 9790411. doi:10.1016/S0033-0620(98)80006-6.
"Is there a "best" statin drug?". The Johns Hopkins Medical Letter Health After 50 15 (11): 4–5. Jan 2004. PMID 14983817.
Lin YL, Wang TH, Lee MH, Su NW (Jan 2008). "Biologically active components and nutraceuticals in the Monascus-fermented rice: a review". Applied Microbiology and Biotechnology 77 (5): 965–73. PMID 18038131. doi:10.1007/s00253-007-1256-6.
Flores NA (Sep 2004). "Ezetimibe + simvastatin (Merck/Schering-Plough)". Current Opinion in Investigational Drugs 5 (9): 984–92. PMID 15503655.
Arnaud C, Veillard NR, Mach F (Apr 2005). "Cholesterol-independent effects of statins in inflammation, immunomodulation and atherosclerosis". Current Drug Targets. Cardiovascular & Haematological Disorders 5 (2): 127–34. PMID 15853754. doi:10.2174/1568006043586198.
Sorrentino S, Landmesser U (Dec 2005). "Nonlipid-lowering effects of statins". Current Treatment Options in Cardiovascular Medicine 7 (6): 459–466. PMID 16283973. doi:10.1007/s11936-005-0031-1.
Stüve O, Youssef S, Steinman L, Zamvil SS (Jun 2003). "Statins as potential therapeutic agents in neuroinflammatory disorders". Current Opinion in Neurology 16 (3): 393–401. PMID 12858078. doi:10.1097/01.wco.0000073942.19076.d1 (inactivo 2015-01-01).
Thorpe JL, Doitsidou M, Ho SY, Raz E, Farber SA (Feb 2004). "Germ cell migration in zebrafish is dependent on HMGCoA reductase activity and prenylation". Developmental Cell 6 (2): 295–302. PMID 14960282. doi:10.1016/S1534-5807(04)00032-2.
Eisa-Beygi S, Hatch G, Noble S, Ekker M, Moon TW (Jan 2013). "The 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) pathway regulates developmental cerebral-vascular stability via prenylation-dependent signalling pathway". Developmental Biology 373 (2): 258–266. PMID 23206891. doi:10.1016/j.ydbio.2012.11.024.
Meigs TE, Roseman DS, Simoni RD (Apr 1996). "Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo". The Journal of Biological Chemistry 271 (14): 7916–22. PMID 8626470. doi:10.1074/jbc.271.14.7916. Arquivado dende o orixinal o 13 de outubro de 2008. Consultado o 22 de xaneiro de 2016.
Meigs TE, Simoni RD (Sep 1997). "Farnesol as a regulator of HMG-CoA reductase degradation: characterization and role of farnesyl pyrophosphatase". Archives of Biochemistry and Biophysics 345 (1): 1–9. PMID 9281305. doi:10.1006/abbi.1997.0200.
Keller RK, Zhao Z, Chambers C, Ness GC (Apr 1996). "Farnesol is not the nonsterol regulator mediating degradation of HMG-CoA reductase in rat liver". Archives of Biochemistry and Biophysics 328 (2): 324–30. PMID 8645011. doi:10.1006/abbi.1996.0180.
Istvan ES, Palnitkar M, Buchanan SK, Deisenhofer J (Mar 2000). "Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis". The EMBO Journal 19 (5): 819–30. PMC 305622. PMID 10698924. doi:10.1093/emboj/19.5.819.
Goldstein JL, Brown MS (Feb 1990). "Regulation of the mevalonate pathway". Nature 343 (6257): 425–30. PMID 1967820. doi:10.1038/343425a0.
Hardie DG, Scott JW, Pan DA, Hudson ER (Jul 2003). "Management of cellular energy by the AMP-activated protein kinase system". FEBS Letters 546 (1): 113–20. PMID 12829246. doi:10.1016/S0014-5793(03)00560-X.
Witters LA, Kemp BE, Means AR (Jan 2006). "Chutes and Ladders: the search for protein kinases that act on AMPK". Trends in Biochemical Sciences 31 (1): 13–6. PMID 16356723. doi:10.1016/j.tibs.2005.11.009.

springer.com

link.springer.com

Sorrentino S, Landmesser U (Dec 2005). "Nonlipid-lowering effects of statins". Current Treatment Options in Cardiovascular Medicine 7 (6): 459–466. PMID 16283973. doi:10.1007/s11936-005-0031-1.

web.archive.org

Meigs TE, Roseman DS, Simoni RD (Apr 1996). "Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo". The Journal of Biological Chemistry 271 (14): 7916–22. PMID 8626470. doi:10.1074/jbc.271.14.7916. Arquivado dende o orixinal o 13 de outubro de 2008. Consultado o 22 de xaneiro de 2016.